Literature DB >> 8614741

Practical p-value adjustment for optimally selected cutpoints.

S G Hilsenbeck1, G M Clark.   

Abstract

This paper concerns a series of simulations undertaken to examine the effects of two data features--number of cutpoints and true marker prognostic effect size--on three methods of p-value adjustment (asymptotic, P(acor); improved Bonferroni, P(bon); and empirical permutation, P(emp)). H(o) rejection rates for P(emp) and P(bon) are almost indistinguishable from those for an independent validation sample (P(vld)), while those of P(acor) are somewhat conservative, especially when the number of cutpoints is small. Analysis of a new breast cancer prognostic marker, heat shock protein 70, illustrates the methods. These results underscore many of the problems associated with data-derived cutpoints in general, and the need for p-value adjustment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8614741     DOI: 10.1002/(SICI)1097-0258(19960115)15:1<103::AID-SIM156>3.0.CO;2-Y

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  16 in total

1.  Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma.

Authors:  Heather L Gustafson; Song Yao; Bryan H Goldman; Kristy Lee; Catherine M Spier; Michael L LeBlanc; Lisa M Rimsza; James R Cerhan; Thomas M Habermann; Brian K Link; Matthew J Maurer; Susan L Slager; Daniel O Persky; Thomas P Miller; Richard I Fisher; Christine B Ambrosone; Margaret M Briehl
Journal:  Am J Hematol       Date:  2014-04-12       Impact factor: 10.047

2.  S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma.

Authors:  Lawrence P Leichman; Bryan H Goldman; Pierre O Bohanes; Heinz J Lenz; Charles R Thomas; Kevin G Billingsley; Christopher L Corless; Syma Iqbal; Philip J Gold; Jacqueline K Benedetti; Kathleen D Danenberg; Charles D Blanke
Journal:  J Clin Oncol       Date:  2011-10-24       Impact factor: 44.544

Review 3.  The importance of identifying and validating prognostic factors in oncology.

Authors:  Susan Halabi; Kouros Owzar
Journal:  Semin Oncol       Date:  2010-04       Impact factor: 4.929

4.  Optimal partitioning for the proportional hazards model.

Authors:  Usha Govindarajulu; Thaddeus Tarpey
Journal:  J Appl Stat       Date:  2020-11-18       Impact factor: 1.416

5.  Comparison of a new microplate oestrogen receptor (ER) enzyme immunoassay with other ER detection methods.

Authors:  V Delage; S Deytieux; V Le Doussal; F Degorce; L Bellanger; K Hacene; P Seguin; F Descotes; S Saez; F Spyratos
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  cSurvival: a web resource for biomarker interactions in cancer outcomes and in cell lines.

Authors:  Xuanjin Cheng; Yongxing Liu; Jiahe Wang; Yujie Chen; Andrew Gordon Robertson; Xuekui Zhang; Steven J M Jones; Stefan Taubert
Journal:  Brief Bioinform       Date:  2022-05-13       Impact factor: 13.994

7.  Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer.

Authors:  Zhong Zheng; Xueli Li; Michael J Schell; Tingan Chen; David Boulware; Lary Robinson; Eric Sommers; Gerold Bepler
Journal:  Cancer       Date:  2008-06-15       Impact factor: 6.860

8.  Redefining adequate margins in oral squamous cell carcinoma: outcomes from close and positive margins.

Authors:  Prateek V Jain; Rajeev Sharan; Kapila Manikantan; Gary M Clark; Sanjoy Chatterjee; Indranil Mallick; Paromita Roy; Pattatheyil Arun
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-01-02       Impact factor: 2.503

9.  Polychotomization of continuous variables in regression models based on the overall C index.

Authors:  Harukazu Tsuruta; Leon Bax
Journal:  BMC Med Inform Decis Mak       Date:  2006-12-14       Impact factor: 2.796

10.  Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods.

Authors:  C Bouchet; F Spyratos; K Hacène; L Durcos; V Bécette; J Oglobine
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.